Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 14, Issue , 2014, Pages 1-64

  Sy, Sherwin K B ^b   Wang, Xiaofeng ^c   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Otsuka Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THIOPENTAL;

ALLOMETRY; ARTICLE; CLEARANCE; COMPARTMENT MODEL; DISEASE COURSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ECHOGRAPHY; FLOW LIMITED ASSUMPTION; HUMAN; KINETICS; LUNG ALVEOLUS; MATHEMATICAL MODEL; MEMBRANE TRANSPORT; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PHARMACOMETRICS; PHYSICAL CHEMISTRY; PROBABILITY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 85065457775     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1304-6_1     Document Type: Article

References (169)

1. Agerso H, Vicini P (2003) Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 19(2–3):141–150.
2. Agoram B, Heatherington AC, Gastonguay MR (2006) Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 8(3):E552–E563.
3. Agresti A (1999) Modelling ordered categorical data: recent advances and future challenges. Stat Med 18(17–18):2191–2207.
4. Andersen ME, Gargas ML, Ramsey JC (1984) Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. Toxicol Appl Pharmacol 73(1):176–187.
5. Andersen ME, Clewell HJ III, Gargas ML, Smith FA, Reitz RH (1987) Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87(2):185–205.
6. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50(5):1641–1650.
7. Bass RF (2011) Stochastic processes, edn. Cambridge University Press, Cambridge
8. Baxter LT, Zhu H, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54(6):1517–1528.
9. Bellman RE, Jacquez JA, Kalaba RE, Kotkin B (1963) A mathematical model of drug distribution in the body: implications for cancer chemotherapy. Rand Corporation, Santa Monica, California.
10. Benet LZ (2010) Clearance (nee Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn 37(6):529–539.
11. Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68(8):1071–1074.
12. Benincosa L, Jusko W (1999) Novel method of treatment. World Intellectual Property Organization, Geneva, Publ. no. W0/2000/027341.
13. Bergman RN, Ider YZ, Bowden CR, Cobelli C (1979) Quantitative estimation of insulin sensitivity. Am J Physiol 236(6):E667–E677.
14. Bernards JK (1986) A pharmacokinetic model for lung uptake of volatile chemicals. MChE, University of Delaware, Newark, DE (Master’s thesis, advisor: K. Bischoff)
15. Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V et al (2005) Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 7(3):E503–512.
16. Bischoff KB (1966) Drug distribution in mammals. Chem Eng Med Biol 62(66): 33–45.
17. Bischoff KB (1975) Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep Part 1 59(4):777–793.
18. Bischoff KB (1987) Physiologically based pharmacokinetic modeling, edn, Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. National Academy Press, Washington, DC.
19. Bischoff KB (1992) PBPK models: what are we really assuming? Presentation at the Chemical Industry Institute of Toxicology Founders Award
20. Bischoff KB, Dedrick RL (1968) Thiopental pharmacokinetics. J Pharm Sci 57(8):1346–1351.
21. Bischoff KB, Dedrick RL, Zaharko DS (1970) Preliminary model for methotrexate pharmacokinetics. J Pharm Sci 59(2):149–154.
22. Bizzotto R, Zamuner S, De Nicolao G, Karlsson MO, Gomeni R (2010) Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J Pharmacokinet Pharmacodyn 37(2):137–155.
23. Bizzotto R, Zamuner S, Mezzalana E, De Nicolao G, Gomeni R, Hooker AC et al (2011) Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis. AAPS J 13(3):445–463.
24. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304(6823):339–343.
25. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10(2):201–227.
26. Boxenbaum H, Ronfeld R (1983) Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245(6):R768–R775.
27. Brandfonbrener M, Landowne M, Shock NW (1955) Changes in cardiac output with age. Circulation 12(4):557–566.
28. Brindley PG, Dunn WF (2009) Simulation for clinical research trials: a theoretical outline. J Crit Care 24(2):164–167.
29. Brown R, Delp M, Lindstedt S, Rhomberg L, Beliles R (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13407:484.
30. Burnham KP, Anderson DR (2002) Model selection and multi-model inference: a practical information- theoretic approach, Second edn. Springer
31. Chen HS, Gross JF (1979) Physiologically based pharmacokinetic models for anticancer drugs. Cancer Chemother Pharmacol 2(2):85–94.
32. Collett D (1994) Modelling survival data in medical research, 1st edn. Chapman & Hall, New York
33. Collins JM, Dedrick RL (1983) Distributed model for drug delivery to CSF and brain tissue. Am J Physiol 245(3):R303–R310.
34. Coxson PG, Bischoff KB (1987a) Lumping strategy. 1. Introductory techniques and applications of cluster analysis. Ind Eng Chem Res 26(6):1239–1248.
35. Coxson PG, Bischoff KB (1987b) Lumping strategy. 2. System theoretic approach. Ind Eng Chem Res 26(10):2151–2157.
36. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F et al (1998) Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 21(1):104–110.
37. Cullberg M, Eriksson UG, Wahlander K, Eriksson H, Schulman S, Karlsson MO (2005) Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther 77(4):279–290.
38. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharma 21(4):457–478.
39. De Gaetano A, Arino O (2000) Mathematical modelling of the intravenous glucose tolerance test. J Math Biol 40(2):136–168
40. de Winter W, DeJongh, Moules I et al (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2. Diabetes Mellitus. J Pharmacokinet Pharmacodyn 33(3):313–343.
41. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharma 1(5):435–461.
42. Dedrick RL, Bischoff KB (1980) Species similarities in pharmacokinetics. Fed Proc 39(1):54–59.
43. Derendorf H, Hochhaus G (1995) Handbook of pharmacokinetics/pharmacodynamics correlation, CRC Press, Boca Raton, FL
44. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R et al (2000) Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40(12. Pt 2):1399–1418.
45. DiSanto AR, Wagner JG (1972) Pharmacokinetics of highly ionized drugs. 3. Methylene blue– blood levels in the dog and tissue levels in the rat following intravenous administration. J Pharm Sci 61(7):1090–1094.
46. Dunne A (1993) Statistical moments in pharmacokinetics: models and assumptions. J Pharm Pharmacol 45(10):871–875.
47. European agency for the evaluation of medicinal products (2007) Guideline on reporting the results of population pharmacokinetic analyses. CHMP/EWP/185990/06 (available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf)
48. Ette EI, Sun H, Ludden TM (1998) Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol 38(5):417–423.
49. Frank GT (1982) A physiological pharmacokinetic model of the lung. MChE, University of Delaware, Newark (Master’s thesis, advisor: K. Bischoff)
50. Freedson P, Katch VL, Sady S, Weltman A (1979) Cardiac output differences in males and females during mild cycle ergometer exercise. Med Sci Sports 11(1):16–19.
51. Frey N, Laveille C, Paraire M, Francillard M, Holford NH, Jochemsen R (2003) Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol 55(2):147–157.
52. Fuller LM, Banker FL, Butler JJ, Gamble JF, Sullivan MP (1975) The natural history of non- Hodgkin’s lymphomata stages I and II. Br J Cancer Suppl 2:270–285.
53. Gabrielsson J, Weiner D (2007) Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, Fourth edn. Swedish Pharmaceutical Press
54. Gall MA, Nielsen FS, Smidt UM, Parving HH (1993) The course of kidney function in type 2 (noninsulin- dependent) diabetic patients with diabetic nephropathy. Diabetologia 36(10):1071–1078.
55. Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72(10):1103–1127.
56. Gibaldi M, Perrier D (1999) Pharmacokinetics: revised and expanded. Drugs Pharma Sci 92:15–15.
57. Gomeni R, Teneggi V, Iavarone L, Squassante L, Bye A (2001) Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling. Pharma Res 18(4):537–543.
58. Grantham JJ, Cook LT, Torres VE, Bost JE, Chapman AB, Harris PC et al (2008) Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int 73(1):108–116.
59. Grehant N (1904a) Mesure de l’activite physio-logique des reins par le dosage de l’ure’e dans le sang et dans l’urine. J Physiol et Path Gen 7:1.
60. Grehant N (1904b) Physiologique des reins par le dosage de l’uree dans le sang et daus l’urine. J physiol (Paris) 6:1–8.
61. Gupta SK, Sathyan G, Lindemulder EA, Ho PL, Sheiner LB, Aarons L (1999) Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther 65(6):672–684.
62. Guyton AC, Hall JE (1996) Textbook of medical physiology, 9th edn. Saunders, Philadelphia;
63. Guyton AC (2011) Guyton and hall textbook of medical physiology, 12th edn. Saunders, Philadelphia
64. Hamren B, Bjork E, Sunzel M, Karlsson M (2008) Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 84(2):228–235.
65. Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis, edn. Springer
66. Heiberger RM, Holland B (2004) Statistical analysis and data display: an intermediate course with examples in S-plus, R, and SAS, edn. Springer Herman WH (2003) Diabetes modeling. Diabetes Care 26(11):3182–3183.
67. Holford N (2013) A time to event tutorial for pharmacometricians. CPT Pharmacometrics Syst Pharmacol 2:e43.
68. Holford NH, Peace KE (1992a) Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A 89(23):11466–11470.
69. Holford NH, Peace KE (1992b) Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A 89(23):11471–11475.
70. Holford N, Ma SC, Ploeger BA (2010) Clinical trial simulation: a review. Clin Pharmacol Ther 88(2):166–182.
71. Hougaard P (1995) Frailty models for survival data. Lifetime Data Anal 1(3):255–273.
72. Hu TM, Hayton WL (2001) Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3(4):E29.
73. Huang SM (2012) PBPK as a tool in regulatory review. Biopharm Drug Dispos 33(2):51–52.
74. Huang SM, Rowland M (2012) The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 91(3):542–549.
75. Hutter JC, Luu HM, Mehlhaff PM, Killam AL, Dittrich HC (1999) Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropanealbumin microsphere sonographic contrast agent. J Ultrasound Med 18(1):1–11.
76. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M et al (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21(13):2492–2499.
77. Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56(4):406–419.
78. Karlsson MO, Schoemaker RC, Kemp B, Cohen AF, van Gerven JM, Tuk B et al (2000) A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin Pharmacol Ther 68(2):175–188.
79. Kemp B, Kamphuisen HA (1986) Simulation of human hypnograms using a Markov chain model. Sleep 9(3):405–414.
80. Kimko HC, Peck CC (2011) Clinical trial simulations: applications and trends, edn. Springer, New York
81. Kimko HC, Reele SS, Holford NH, Peck CC (2000) Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 68(5):568–577.
82. Kjellsson MC, Zingmark PH, Jonsson EN, Karlsson MO (2008) Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. J Pharmacokinet Pharmacodyn 35(5):483–501.
83. Knibbe CA, Zuideveld KP, DeJongh J, Kuks PF, Aarts LP, Danhof M (2002) Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6 % and propofol 1 %. Clin Pharmacol Ther 72(6):670–684.
84. Kowalski KG, Hutmacher MM (2001) Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 20(1):75–91.
85. Kowalski KG, McFadyen L, Hutmacher MM, Frame B, Miller R (2003) A two-part mixture model for longitudinal adverse event severity data. J Pharmacokinet Pharmacodyn 30(5):315–336.
86. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE (2009) A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther 86(4):387–395.
87. Landersdorfer CB, Jusko WJ (2008) Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet 47(7):417–448.
88. Lee PI (2001) Design and power of a population pharmacokinetic study. Pharma Res 18(1):75–82.
89. Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM et al (2012) Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther 91(5):926–931.
90. Lewis AE (1948) The concept of hepatic clearance. Am J Clin Pathol 18(10):789–795.
91. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329(20):1456–1462.
92. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X et al (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313(3):1254–1262.
93. Lunn DJ, Wakefield J, Racine-Poon A (2001) Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores. Stat Med 20(15):2261–2285.
94. Mager DE, Abernethy DR, Egan JM, Elahi D (2004) Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 311(2):830–835.
95. Maiwald T, Timmer J (2008) Dynamical modeling and multi-experiment fitting with Potters- Wheel. Bioinformatics 24(18):2037–2043.
96. Mandema JW, Stanski DR (1996) Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 60(6):619–635.
97. McCullagh P (1980) Regression models for ordinal data. J R Stat Soc B 42(2): 109–142.
98. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S et al (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 11(3):582–593.
99. Meibohm B, Laer S, Panetta JC, Barrett JS (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7(2):E475–E487.
100. Metcalfe C, Thompson SG (2007) Wei, Lin and Weissfeld’s marginal analysis of multivariate failure time data: should it be applied to a recurrent events outcome? Stat Methods Med Res 16(2):103–122.
101. Mordenti J, Chappell W (1989) The use of interspecies scaling in toxicokinetics. In: Yacobi A, Skelly JP, Batra V (eds) Toxicokinetics and new drug development, edn. Pergamon, New York, pp 42–96.
102. Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J (2001) A population pharmacokinetic- pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Ther 69(4):210–222.
103. Mould DR (2007) Developing models of disease progression. In: Ette EI, Williams PJ (eds) Pharmacometrics: the science of quantitative pharmacology, edn. Wiley, Hoboken, pp 547–581.
104. Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H et al (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71(5):334–348.
105. Mould DR, Denman NG, Duffull S (2007) Using disease progression models as a tool to detect drug effect. Clin Pharmacol Ther 82(1):81–86.
106. Nestorov IA, Aarons LJ, Arundel PA, Rowland M (1998) Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharma 26(1):21–46.
107. Nielsen EI, Friberg LE (2013) Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 65(3):1053–1090.
108. Ogungbenro K, Aarons L (2008) How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach. Eur J Clin Pharmacol 64(7):705–713.
109. Oliver RE, Jones AF, Rowland M (2001) A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J Pharmacokinet Pharmacodyn 28(1):27–55.
110. Olofsen E, Romberg R, Bijl H, Mooren R, Engbers F, Kest B et al (2005) Alfentanil and placebo analgesia: no sex differences detected in models of experimental pain. Anesthesiology 103(1):130–139.
111. Ouellet D, Sutherland S, Wang T, Griffini P, Murthy V (2011) First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: relationship between exposure and dizziness. Clin Pharmacol Ther 90(4):597–604.
112. Pacini G, Bergman RN (1986) MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Compute Methods Programs Biomed 23(2):113–122.
113. Pang KS, Durk MR (2010) Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn 37(6):591–615.
114. Parving HH, Rossing P, Hommel E, Smidt UM (1995) Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years’ experience. Am J Kidney Dis 26(1):99–107.
115. Peters RH (1986) The ecological implications of body size, edn, Cambridge University Press
116. Peters SA (2008) Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47(4):261–275.
117. Peters SA (2012) Physiologically-based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry, First edn. Wiley
118. Peters SA, Hultin L (2008) Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentrationtime profiles in rat. J Pharmacokinet Pharmacodyn 35(1):1–30.
119. Peterson B, Harrell Jr FE (1990) Partial proportional odds models for ordinal response variables. Appl Stat 39(2): 205–217.
120. Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer JL (2004) A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 58(6):618–631.
121. Pors Nielsen S, Barenholdt O, Hermansen F, Munk-Jensen N (1994) Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol 101(4):319–324.
122. Poulin P, Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89(1):16–35.
123. Poulin P, Theil FP (2002a) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanismbased prediction of volume of distribution. J Pharm Sci 91(1):129–156.
124. Poulin P, Theil FP (2002b) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91(5):1358–1370.
125. Poulin P, Schoenlein K, Theil FP (2001) Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90(4):436–447.
126. Ramsey JC, Andersen ME (1984) A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol 73(1):159–175.
127. Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM (2009) Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 68(5):669–681.
128. Reddy M, Yang R, Andersen ME, Clewell III HJ (2005) Physiologically based pharmacokinetic modeling: science and applications, First edn. Wiley-Interscience
129. Rosch J, Antonovic R, Trenouth RS, Rahimtoola SH, Sim DN, Dotter CT (1976) The natural history of coronary artery stenosis. A longitudinal angiographic assessment. Radiology 119(3):513–520.
130. Ross SM (2006) Introduction to probability models, edn. Access Online via Elsevier
131. Rowland M (1972) Application of clearance concepts to some literature data on drug metabolism in the isolated perfused liver preparation and in vivo. Eur J Pharmacol 17(3):352–356.
132. Rowland M, Tozer TN (1989) Clinical pharmacokinetics: concepts and applications, edn, vol. 162. Lea & Febiger, Philadelphia
133. Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharma 1(2):123–136.
134. Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol and Toxicol 51:45–73.
135. Sadray S, Jonsson EN, Karlsson MO (1999) Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection. Pharm Res 16(8):1260–1265.
136. Savage VM, Gillooly J, Woodruff W, West G, Allen A, Enquist B et al (2004) The predominance of quarter-power scaling in biology. Funct Ecol 18(2):257–282.
137. Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558–569.
138. Schmidt S, Post TM, Boroujerdi MA, van Kesteren C, Ploeger BA, Della Pasqua OE et al (2011) Disease progression analysis: towards mechanism-based models. In: Kimko HC, Peck CC (eds) Clinical trial simulations, edn. Springer, New York, pp 433–455.
139. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L et al (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2(77):ra31.
140. Sheiner LB, Ludden TM (1992) Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 32:185–209.
141. Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharma 5(5):445–479.
142. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25(3):358–371.
143. Sy SK, Heuberger J, Shilbayeh S, Conrado DJ, Derendorf H (2013a) A Markov Chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. AAPS J 15(4):1189–99.
144. Sy SK, Singh RP, Shilbayeh S, Zmeili R, Conrado D, Derendorf H (2013b) Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. Clin Pharmacol Drug Dev 2(1):67–78.
145. Teorell T (1937a) Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration. Arch Int pharmacodyn Ther 57:205–225.
146. Teorell T (1937b) Kinetics of distribution of substances administered to the body, II: the intravascular modes of administration. Arch Int Pharmacodyn Ther 57:226–240.
147. Theil FP, Guentert TW, Haddad S, Poulin P (2003) Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138(1–2):29–49.
148. Thomaseth K, Salvan A (1998) Estimation of occupational exposure to 2,3,7,8-tetrachlorodibenzop- dioxin using a minimal physiologic toxicokinetic model. Environ Health Perspect 106(Suppl 2):743–753.
149. Troconiz IF, Plan EL, Miller R, Karlsson MO (2009) Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn 36(5):461–477.
150. U.S. Department of Health and Human Services, Food and Drug Administration. DA (1999) Guidance for industry: population pharmacokinetics, (available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf)
151. van der Molen GW, Kooijman SA, Slob W (1996) A generic toxicokinetic model for persistent lipophilic compounds in humans: an application to TCDD. Fundam Appl Toxicol 31(1):83–94.
152. Venables WN, Ripley BD, Venables W (1994) Modern applied statistics with S-PLUS, edn, vol. 250. Springer, New York
153. Vong C, Bergstrand M, Nyberg J, Karlsson MO (2012) Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J 14(2):176–186.
154. Wada DR, Bjorkman S, Ebling WF, Harashima H, Harapat SR, Stanski DR (1997) Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 87(4):884–899.
155. Wang X, Santostefano MJ, Evans MV, Richardson VM, Diliberto JJ, Birnbaum LS (1997) Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague- Dawley rats. Toxicol Appl Pharmacol 147(1):151–168.
156. Wei L, Glidden DV (1997) An overview of statistical methods for multiple failure time data in clinical trials. Stat Med 16(8):833–839.
157. Wei L-J, Lin DY, Weissfeld L (1989) Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84(408):1065–1073.
158. West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276(5309):122–126.
159. West GB, Brown JH, Enquist BJ (1999) The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284(5420):1677–1679.
160. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39(1):1–47.
161. Wilkinson GR, Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18(4):377–390.
162. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72(3):265–275.
163. Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharma 6(6):547–558.
164. Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W et al (2012) The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol 53(2):160–6.
165. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H (2005) Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 45(3):246–256.
166. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V et al (2009) Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86(6):609–618.
167. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ et al (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89(2):259–267.
168. Zhao P, Rowland M, Huang SM (2012) Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92(1):17–20.
169. Zingmark PH, Ekblom M, Odergren T, Ashwood T, Lyden P, Karlsson MO et al (2003) Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol 56(2):173–183